Munich Re logo
Not if, but how
Munich Re Life US

Explore Munich Re Group

Get to know our Group companies, branches and subsidiaries worldwide.

The long-term complications of COVID-19 infection
0.5 minutes read
Published 2024/08/26
Close-up portrait of a beautiful young woman wearing a mask getting vaccinated.
© Andriy Onufriyenko / Getty Images
    alt txt

    properties.trackTitle

    properties.trackSubtitle

    Reports of long-term morbidity and mortality following Covid-19 infection are now attracting attention. Recent studies suggest that COVID-19 survivors are at increased risk of common illnesses, such as myocardial infarction, diabetes mellitus, and autoimmune disorders. Mortality may also be increased. In this article in the Journal of Insurance Medicine, Munich Re’s Dr. Tim Meagher reviews the evidence that supports some of these observations and provides an opinion about their validity and relevance to insured cohorts. 
    Read full article
    Contact the Author
    Tim Meagher
    Dr. Tim Meagher
    Vice President & Medical Director
    Munich Re, Canada (Life)
    Email
    tmeagher@munichre.ca

    This may interest you

    two lab technicians working on a computer
    Clinical Knowledge
    Long Covid - Into the third year
    Dr. Tim Meagher provides an update on long Covid, with a particular focus on disease prevalence, disability, and risk factors.
    0.5 minutes read
    Published 2023/06/27
    COVID-Related Mortality Projections – Value in Accuracy
    Future of Risk
    COVID-related mortality projections
    Munich Re’s mortality projections have proven to be more accurate than the publicly available US mortality forecasts.
    3.5 minutes read
    Published 2022/08/30
    Doctor showing patient tablet with holographic medical report
    Clinical Knowledge
    Diabetes following COVID-19: Is it common?
    Dr. Tim Meagher examines the increase in both type 1 and type 2 diabetes that has occurred during the pandemic.
    0.5 minutes read
    Published 2024/06/27
    Electronic health record
    Clinical Knowledge
    Could obesity drugs reduce heart disease?
    What's the potential for GLP-1 agonists to reduce risk factors for heart disease?
    4 minutes read
    Published 2024/02/07

    Newsletter

    Subscribe to our newsletter for the latest industry research, insights on life and health-related topics, and relevant Munich Re Life US updates. Join today and stay connected with our business.
    Subscribe now